Zhou Cheng-Hua, Wan Ya-Ya, Chu Xiang-Hua, Song Zheng, Xing Shu-Hua, Wu Yu-Qing, Yin Xiao-Xing
School of Pharmacy, Xuzhou Medical College, Xuzhou, Jiangsu 221004;
Oncol Lett. 2012 Dec;4(6):1259-1263. doi: 10.3892/ol.2012.932. Epub 2012 Sep 21.
Urotensin II (UII), a somatostatin-like cyclic peptide, was originally isolated from the fish urophysis. Our previous study showed that UII stimulates the proliferation of A549 lung adenocarcinoma cells and promotes tumor growth in a nude mouse xenograft model, suggesting that UII may contribute to the pathogenesis of lung adenocarcinoma. In this study, the underlying mechanism for UII to promote lung adenocarcinoma growth was explored by observing the effect of UII on the tumor inflammatory microenvironment in tumor-bearing nude mice. Immunohistochemical analysis showed that UII promoted the infiltration of CD68(+) tumor-associated macrophages (TAMs) in the tumor micro-environment. Enzyme-linked immunosorbent assay (ELISA) demonstrated that UII promoted the release of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and matrix metalloproteinase-9 (MMP-9). Western blot analysis showed that UII promoted the activation of nuclear factor-κB (NF-κB). These findings suggest that the enhanced levels of IL-6, TNF-α and MMP-9 in the tumor microenvironment, which likely resulted from increased activation of NF-κB induced by UII, may be one of the important mechanisms by which UII promotes lung adenocarcinoma growth. These findings imply that antagonists of UII or urotensin II-receptor (UT-R) have potential for the prevention and treatment of lung adenocarcinoma.
尾加压素 II(UII)是一种类似生长抑素的环肽,最初是从鱼的尾垂体中分离出来的。我们之前的研究表明,UII 可刺激 A549 肺腺癌细胞的增殖,并在裸鼠异种移植模型中促进肿瘤生长,这表明 UII 可能参与肺腺癌的发病机制。在本研究中,通过观察 UII 对荷瘤裸鼠肿瘤炎症微环境的影响,探讨了 UII 促进肺腺癌生长的潜在机制。免疫组织化学分析表明,UII 促进了肿瘤微环境中 CD68(+)肿瘤相关巨噬细胞(TAM)的浸润。酶联免疫吸附测定(ELISA)表明,UII 促进了白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)和基质金属蛋白酶-9(MMP-9)的释放。蛋白质印迹分析表明,UII 促进了核因子-κB(NF-κB)的激活。这些发现表明,肿瘤微环境中 IL-6、TNF-α 和 MMP-9 水平的升高可能是 UII 促进肺腺癌生长的重要机制之一,而这可能是由 UII 诱导的 NF-κB 激活增加所致。这些发现意味着 UII 或尾加压素 II 受体(UT-R)拮抗剂在肺腺癌的预防和治疗方面具有潜力。